Business
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 Post-offering cash, cash equivalents and marketable securities expected to fund Company through BLA for ORKA-001 MENLO PARK, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel bio
About this update from Oruka Therapeutics, Inc.
[{"type":"image","alt":"Oruka Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Oruka Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/08c71a601d6ce82817d03b992189e527"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JeJLZVqxW8mfY231yA2EUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/08c71a601d6ce82817d03b992189e527","width":300,"height":102},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/JeJLZVqxW8mfY231yA2EUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/08c71a601d6ce82817d03b992189e527","width":300,"height":102}},"lazy":false},{"type":"text","content":"ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026","length":139,"tagName":"p"},{"type":"text","content":"ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027","length":83,"tagName":"p"},{"type":"text","content":"Post-offering cash, cash equivalents and marketable securities expected to fund Company through BLA for ORKA-001","length":112,"tagName":"p"},{"type":"text","content":"MENLO PARK, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported first quarter 2026 financial results and provided a corporate update.","length":362,"tagName":"p"},{"type":"text","content":"“This was an important period for our company as we saw interim data for ORKA-001 that hit the upper end of our expectations on all aspects,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka. “Based on this data we were able to strengthen our balance sheet and provide runway through completion of late-stage development for that program. We’re looking forward to multiple readouts coming in 2026 and 2027, including additional data from ORKA-001 and the beginning of our readouts for ORKA-002 as well.”","length":513,"tagName":"p"},{"type":"text","content":"First Quarter 2026 and Recent Business and Pipeline Updates","length":59,"tagName":"p"},{"type":"text","content":"ORKA-001: A...